Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Epiduo 0.3 %/2.5 % gel
Medicines register · Ireland

Epiduo 0.3 %/2.5 % gel

Authorisation PA25691/005/002 · Galderma S.A. the Netherlands Branch

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 22 Nov 2026
Licence holder
Galderma S.A. the Netherlands Branch (all products →)
Active substances
Adapalene, Anhydrous Benzoyl Peroxide
Clinical trials
2 clinical trials →
Dosage form
Gel
Route of administration
Cutaneous use
ATC code
D10AD53
First authorised
14/10/2022
Prescription status
Product subject to prescription which may not be renewed (A)
Supply
Supply through pharmacies only
Legal basis
Fixed combination application (Article 10b of Directive No 2001/83/EC)

Adapalene: supply and approvals

9 authorised products on the HPRA list contain Adapalene. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 21 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 21 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 21 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

Anhydrous Benzoyl Peroxide: supply and approvals

3 authorised products on the HPRA list contain Anhydrous Benzoyl Peroxide. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 21 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 21 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 21 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 4 years (since 14 October 2022). The HPRA list marks it as not marketed: it is licensed but the holder has not reported it as on sale.

Other medicines with Adapalene in Ireland

8 other products on the HPRA list contain Adapalene, from 4 licence holders; 2 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Differin 0.1% w/w GelGalderma InternationalNational authorisation (PA)Marketed
Epiduo 0.1%/2.5% gelGalderma S.A. the Netherlands BranchNational authorisation (PA)Marketed
Differin 0.1% w/w CreamGalderma InternationalNational authorisation (PA)Not marketed
Differin 0.1% w/w CreamPCO Manufacturing Ltd.Parallel import (PPA)Not stated
Differin 0.1% w/w creamIMED Healthcare Ltd.,Parallel import (PPA)Not stated
Differin 0.1% w/w gelPCO Manufacturing Ltd.Parallel import (PPA)Not stated
Differin 0.1% w/w gelIMED Healthcare Ltd.,Parallel import (PPA)Not stated
Epiduo 0.1%/2.5% gelPCO Manufacturing Ltd.Parallel import (PPA)Not stated

Other medicines with Anhydrous Benzoyl Peroxide in Ireland

2 other products on the HPRA list contain Anhydrous Benzoyl Peroxide, from 2 licence holders; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Clindamycin + Benzoyl Peroxide 10 mg/g + 50 mg/g gelAspire Pharma (Malta) LimitedNational authorisation (PA)Not marketed
Duac Once Daily 10 mg/g + 50 mg/g gelPCO Manufacturing Ltd.Parallel import (PPA)Not stated

The licence holder

Galderma S.A. the Netherlands Branch holds 7 products on the HPRA list, with 8 different active substances; 4 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 22 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.